Role of chemokines and their receptors in chronic lymphocytic leukemia Function in microenvironment and targeted therapy

被引：32
作者：
Han, Ting-Ting [1 ]
Fan, Lei [1 ]
Li, Jian-Yong [1 ]
Xu, Wei [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China
来源：
CANCER BIOLOGY & THERAPY | 2014年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
chronic leukemia lymphoma; microenvironment; chemokines; chemokines receptors; targeted therapy; B-CELL RECEPTOR; TYROSINE KINASE INHIBITOR; IN-VITRO; NODE MICROENVIRONMENT; GROWTH-FACTOR; PHASE-II; CXCR4; ACTIVATION; SURVIVAL; PCI-32765;
D O I：
10.4161/cbt.26607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chemokines produced in distinct tissue microenvironments sustain migration of mature lymphocytes in lymphoglandula. Chemokine receptors expressed on chronic lymphocytic leukemia (CLL) cells regulate the migration of the leukemia cells within the bone marrow (BM), lymphoid organs in collaboration with chemokines. Chemokines form a pro-survival circuitry by regulating leukocyte trafficking, maintaining extended lymphocyte survival. Therefore, chemokines in tumor cell-microenvironment interactions represent a target for treatment of CLL. AMD3100 disrupts the CLL/microenvironment interactions and influences CXCL12/CXCR4 survival signaling. Fostamatinib, ibrutinib, GS-1101 as B-cell receptor (BCR) related kinase inhibitors inhibit BCR- and chemokine-receptor-signal-regulated kinase and have a good clinical response in CLL. Lenalidomide, sorafenib, and dasatinib are other additional drugs associated with chemokine in microenvironment. Inhibiting signaling through chemokine and microenvironment associated signaling are emerging as innovative therapeutic targets in CLL. In this article, we reviewed the role of chemokines in CLL microenvironment and novel therapeutics targeting CLL microenvironment.
引用
收藏
页码：3 / 9
页数：7
相关论文
共 74 条
[1]   Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].
Amrein, Philip C. ;
Attar, Eyal C. ;
Takvorian, Tak ;
Hochberg, Ephraim P. ;
Ballen, Karen K. ;
Leahy, Kathleen M. ;
Fisher, David C. ;
LaCasce, Ann S. ;
Jacobsen, Eric D. ;
Armand, Philippe ;
Hasserjian, Robert P. ;
Werner, Lillian ;
Neuberg, Donna ;
Brown, Jennifer R. .
CLINICAL CANCER RESEARCH, 2011, 17 (09) :2977-2986
[2]  
Andritsos LA, 2010, HAEMATOLOGICA, P95
[3]   Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro [J].
Backman, Eva ;
Bergh, Ann-Charlotte ;
Lagerdahl, Irena ;
Rydberg, Bjorn ;
Sundstrom, Christer ;
Tobin, Gerard ;
Rosenquist, Richard ;
Linderholm, Mats ;
Rosen, Anders .
HAEMATOLOGICA, 2007, 92 (11) :1495-1504
[4]   Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [J].
Badoux, Xavier C. ;
Keating, Michael J. ;
Wen, Sijin ;
Wierda, William G. ;
O'Brien, Susan M. ;
Faderl, Stefan ;
Sargent, Rachel ;
Burger, Jan A. ;
Ferrajoli, Alessandra .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :584-591
[5]   Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies [J].
Bandera, Alessandra ;
Verga, Luisa ;
Perseghin, Paolo ;
Incontri, Arianna ;
Pioltelli, Pietro E. ;
Gori, Andrea .
AIDS, 2013, 27 (06) :1037-1039
[6]   R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].
Braselmann, Sylvia ;
Taylor, Vanessa ;
Zhao, Haoran ;
Wang, Su ;
Sylvain, Catherine ;
Baluom, Muhammad ;
Qu, Kunbin ;
Herlaar, Ellen ;
Lau, Angela ;
Young, Chi ;
Wong, Brian R. ;
Lovell, Scott ;
Sun, Thomas ;
Park, Gary ;
Argade, Ankush ;
Jurcevic, Stipo ;
Pine, Polly ;
Singh, Rajinder ;
Grossbard, Elliott B. ;
Payan, Donald G. ;
Masuda, Esteban S. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008
[7]   Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials [J].
Brown, Jennifer R. .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) :1-6
[8]   Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia [J].
Buchner, Maike ;
Baer, Constance ;
Prinz, Gabriele ;
Dierks, Christine ;
Burger, Meike ;
Zenz, Thorsten ;
Stilgenbauer, Stephan ;
Jumaa, Hassan ;
Veelken, Hendrik ;
Zirlik, Katja .
BLOOD, 2010, 115 (22) :4497-4506
[9]  
Burger JA, 2000, BLOOD, V96, P2655
[10]   Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape [J].
Burger, Jan A. .
CURRENT OPINION IN ONCOLOGY, 2012, 24 (06) :643-649
12345678